Wallace Rheumatic Study Center Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2005
NCT00281294
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Alternative names

Wallace Rheumatic Studies Center LLC

Active Ingredients

Drugs in Phase 3 Trials (1)

Rigerimod (1 trial)

Drugs in Phase 2 Trials (1)

fontolizumab (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Lupus Erythematosus, Systemic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 2
  • # of Trial APIs: 2